SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Pusan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world’s leading biotechnology centers and the “birthplace” of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.
View Top Employees from SillaJen Inc.Website | http://www.sillajen.com/ |
Ticker | KOSDAQ:215600 |
Revenue | $8 million |
Employees | 20 (18 on RocketReach) |
Founded | 2003 |
Address | 11th Floor, O2 Tower, 83 Uisadang-daero, Seoul, Seoul, KR |
Phone | (822) 368-2600 |
Fax | (822) 783-7555 |
Technologies |
JavaScript,
HTML,
PHP
+12 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Drug Manufacturing & Research, Oncolytic Immunotherapeutics, Science and Engineering, Cancer Treatment, Healthcare, Business Services, Health Care, Bioengineering, Medical, Clinical R&D |
Web Rank | 1 Million |
Keywords | 신라젠, When Sillajen Inc Got Pexa-Vec, When Pexa-Vec Start Phase 3, Селезенка Увеличена Симптомы, 929 Tk Virus |
Competitors | Actinium Pharmaceuticals, Inc., Alethia Biotherapeutics Inc., Atreca, Inc., ImCheck Therapeutics, Transgene |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies |
Looking for a particular SillaJen Inc. employee's phone or email?
The SillaJen Inc. annual revenue was $8 million in 2023.
Nick Gaspar is the Director of Clinical Assays of SillaJen Inc..
18 people are employed at SillaJen Inc..
SillaJen Inc. is based in Seoul, Seoul.
The NAICS codes for SillaJen Inc. are [325, 3254, 32541, 541, 54, 32].
The SIC codes for SillaJen Inc. are [28, 283].